Nasdaq Stockholm Listing

Alvotech, a global biosimilar medicines developer, commenced trading on Nasdaq Stockholm on May 19, 2025, via an oversubscribed SDR offering (441,600 SDRs at SEK 87.51 each, raising SEK 39M). This triple-listing (including Nasdaq Global and Iceland) enhances liquidity and European investor access, while the pending acquisition of Xbrane Biopharma’s R&D operations in Sweden supports scientific expansion. Despite a 10% SDR price discount and added operational complexity, the move aims to strengthen Nordic presence, diversify funding sources, and capitalize on robust biotech investment interest in Europe.